Introduction
Heredopathia atactica polyneuritiformis was first reported as a clinical entity by Refsum in 1945 (1) . The prominent features of the syndrome include atypical retinitis pigmentosa, hypertrophic peripheral neuropathy, cerebellar ataxia, nerve deafness, and elevated cerebrospinal fluid protein concentration with albuminocytologic dissociation (2) . Although only some 40 cases have been reported, it seems fairly certain that the disease is genetic in origin and transmitted in an autosomal recessive manner (2) (3) (4) .
In 1963 Klenk and Kahlke (5) found that the blood and tissues of patients with Refsum's disease contained high concentrations of an unusual branched-chain fatty acid-phytanic acid (3,7,11, 15-tetramethylhexadecanoic acid) . In the liver of the first patient studied chemically post-mortem, phytanic acid accounted for over 50% of total fatty acids; the relative concentration of phytanic acid in kidney lipids was almost as great (5) . Very similar results in tissues of another patient have been reported by Hansen (6) . Phytanic acid in the plasma can account for anywhere from 3 to 25%o of total fatty acids (7) (8) (9) . The present studies were undertaken to explore the origins of the phytanic acid and the nature of the metabolic error leading to its accumulation.
The polyisoprenoid structure of phytanic acid suggested that it might be biosynthesized by way 313 of mevalonic acid in analogy with the biosynthesis of the branched-chain skeleton of farnesyl pyrophosphate (10) (Figure 1 ). The formation of geranylgeranyl pyrophosphate by addition of a fourth isopentenyl pyrophosphate unit to farnesyl pyrophosphate is a normal step in plants and in yeast on the pathway to carotene formation (11) . Nandi and Porter have shown that a pig liver preparation can catalyze this reaction (12) . As shown in Figure 1 , phytanic acid could be formed from geranylgeranyl pyrophosphate (after elimination of the pyrophosphate group) by reduction of its four double bonds and oxidation of the alcohol function to a carboxylic acid. Although there is no evidence that geranylgeranyl pyrophosphate is formed in significant amounts by mammals under ordinary circumstances, it seemed possible that a genetic error could evoke or accentuate such a pathway, e.g., by inhibiting the rate of condensation of farnesyl pyrophosphate with itself to form squalene. If there were a metabolic block in the breakdown of phytanic acid, then even a limited rate of synthesis could lead to accumulation of the product. One purpose of the present studies was to test for biosynthesis.
Animal studies established that phytol, ubiquitously present in the diet as a component of the chlorophyll molecule, can readily be converted to phytanic acid (13) (14) (15) (16) . Phytanic acid itself is also present in the diet as a minor component in butterfat (17) and ruminant body fats (18, 19) . Normal human and animal sera contain phytanic acid but only at very low concentrations (20, 21) . However, when either phytol or phytanic acid is fed to animals in sufficiently large dosage, phytanic acid accumulates in blood and tissues, and the concentrations can reach levels comparable to those observed in patients with Refsum's disease (13) (14) (15) 22) . If there were a metabolic block in the degradation of phytanic acid, even a low intake of these potential precursors could cause accumulation in affected patients. A second major purpose of the present studies was to explore the metabolism of phytol and phytanic acid in patients with Refsum's disease. Results of these studies have been reported in preliminary form (23) (24) (25) .
Methods
The case histories of our two patients with Refsum's disease (T.E. and K.M.) have been presented in detail elsewhere (9) . A summary of some pertinent laboratory findings at the time of the present studies is given in Table I . The patients were under observation at Rikshospitalet in Oslo; seven normal volunteers were studied at the Clinical Center in Bethesda.
At the time of the phytol-U-"C and D20 1 studies, the patients were on a vegetable-free, low fat diet; on the day preceding the study and for 7 days thereafter, the normal subjects were given a diet lacking green vegetables and dairy products but containing adequate amounts of vitamins and iron. The radioactive preparations were administered after a 12-hour overnight fast, food being withheld for an additional 3 hours after administration. Phytol-U-"C was given orally, dissolved in 10 ml of corn oil or olive oil. The preparation of uniformly labeled phytol-lC has been described elsewhere (13, 16) ; the samples used were 93 to 98% pure by radioassay. Mevalonate-2-"C (98.5% pure by radioassay) was obtained as the dibenzylethylenediamine salt,2 converted to the potassium salt, and given intravenously.
At specified times, respiratory gases were collected over accurately measured 2-minute intervals into evacuated Douglas bags with subjects in a resting state. The total content of each Douglas bag was passed through 5 N NaOH for absorption of C02. The gas train included a Ba(OH)2 trap to detect any loss of C02 in the initial absorption; any BaCO3 formed was also analyzed for radioactivity. The solution containing Na2"CO3 was counted directly on anthracene crystals (26) or was treated with saturated barium hydroxide or barium chloride to precipitate Ba"'CO3 quantitatively. The barium carbonate was either finely ground and suspended in 5%
Cab-O-Sil 3 for radioassay (27) or was treated with sulfuric acid with quantitative collection of the released "CO2 into phenethylamine 4 scintillation medium (28 Results obtained by any of these methods were in good agreement; recovery of radioactivity from known standards of Ba214COa was greater than 95%. Internal standards were used to correct for quenching, and all results were corrected to the same efficiency. All radioactive counting was done in a Packard Tri-Carb scintillation counter. All solvents and reagents were redistilled before use. Total urine and fecal collections were made for at least 4 days in most cases. Urine samples were prepared directly for radioassay in a dioxane-containing scintillation medium (29) ; fecal lipid radioactivity was determined from a sample of uniformly homogenized and suspended feces (30) . Total lipid radioactivity in feces was subtracted from the dose given to estimate the amount of labeled phytol absorbed. As shown in animal studies, some phytol radioactivity appears in bile (31) , and the data for absorption calculated in this way therefore represent minimal values.
Venous blood samples were drawn into heparinized syringes. Plasma lipids were extracted according to the method of Folch, Lees, and Sloane Stanley (32) , and the chloroform phase was analyzed for cholesterol (33) , phospholipids (34) , and triglycerides (35) . Total lipid radioactivity was determined directly from a sample added to 0.4% diphenyloxazole in toluene. Other lipid samples were saponified and further fractionated by solvent partition and either thin layer or gas-liquid chromatography, or both, as described elsewhere (13, 15) . Total plasma nonsaponifiable lipids were subjected to thin layer chromatography (TLC) in benzene-ethyl acetate 4:1 to separate phytol and cholesterol. In the studies with mevalonate-2-14C, cholesterol isolated in this way accounted for 94% of the nonsaponifiable fraction. Fatty acids were extracted with hexane and ether from the acidified mixture after saponification, methylated, and chromatographed on thin layers of silicic acid with benzene-hexane 2:1. The branched-chain acids migrate slightly faster than straight-chain acids in this system, but are not completely resolved from them. When the phytanic acid-containing band was checked by gasliquid chromatography, the methyl phytanate peak generally accounted for 90% or more of the total, but there were always a few smaller peaks corresponding to saturated straight-chain acids.
Body water enrichment with deuterium in subj ect T.E. was obtained by giving an initial dose of 400 ml of 50% D20 by mouth (divided in three portions), an amount calculated to reach approximately 0.5 atom % excess enrichment. Thereafter, single daily doses (40 ml of 50% D20) calculated to replace deuterium lost in turnover of body water were administered to maintain this enrichment. Deuterium enrichment in the water of daily urine samples and approximately biweekly serum samples was determined by infrared spectroscopy (36) in a Beckman IR-7 spectrometer. Atom per cent excess deuterium was held in a narrow range between 0.44 and 0.54, averaging 0.49 over the 130 days of study. Enrichment in plasma cholesterol and in plasma phytanic acid was determined by mass spectrometry with an Associated Electronics Industries MS-9 high resolution instrument.
Cholesterol was purified for mass spectrometry from the plasma nonsaponifiable fraction via the digitonide. Phytanic acid was isolated from the plasma saponifiable fraction by TLC of the methyl esters as described above. To remove any co-chromatographing impurities, we further purified the methyl phytanate isolated by TLC by preparative gas-liquid chromatography. The mass spectra obtained of the purified plasma phytanic acid samples were identical with the spectrum of synthetic methyl phytanate. Free cholesterol and methyl phytanate were introduced directly into the ionization chamber via a probe inlet system. The ratio of the intensity of the peak of deuterium-containing molecules (m/e + 1) to that of the parent peak (m/e), corrected for the natural abundance of (m/e + 1) molecules (due to LIC, 2H, 170), was used to calculate atoms per cent excess deuterium. At the low enrichments encountered, the abundance of (m/e + 2) species could be neglected. Figure 2 , incorporation into plasma cholesterol was comparable to that in a control subject similarly studied; it was also similar to that in a larger series of subjects studied previously (37) . By contrast, there was virtually no incorporation into plasma phytanic acid (Figure 2 ). At (Figure 1 ) would result in incorporation of 14 hydrogen atoms by reductive processes. As discussed below, this number is uncertain since it depends on the extent to which reduced nucleotides exchange with body water. To contrast the results with the cholesterol data, we have calculated and plotted in Figure 3 the incorporation into phytanate on the assumption that complete turnover would result in replacement of 2 of the 39 nonlabile hydrogen atoms in phytanic acid. (Since the methyl ester of phytanic acid was prepared for analysis, the readily exchangeable carboxyl hydrogen was not included in the data analyzed.)
As discussed under Methods, the enrichment in the fragment of the molecule representing carbons 1 through 3 together with the first branch-methyl group could be separately determined in the mass spectrometer. Analysis of the results shows that the small incorporation into the parent molecule observed was largely limited to this terminal fragment. In all of the samples analyzed for enrichment in the 102 fragment, we found that at least three-quarters of the deuterium in the total molecule had been incorporated at this end of the molecule. This might reflect 1) nonenzymatic exchange of the hydrogen adjacent to the carboxyl group; 2) enzymatically catalyzed exchange (desaturation-resaturation occurring in the 2,3 position); or 3) formation of phytanic acid from dietary phytol, a reaction involving hydrogenation of the 2,3 double bond of the latter, or from other unsaturated precursors. In any case, there was no evidence of regular distribution of deuterium along the chain, such as would be expected if phytanic acid were biosynthesized de novo from mevalonate or other low molecular weight precursors.
Metabolism of phytol-U-'4C. Tracer doses (less than 0.5 mg) of phytol-U-14C in 20 to 30 ml of vegetable oil were given orally to two patients with Refsum's disease and to seven normal control subjects. Absorption ranged from 61 to 94%o in control subjects and was 74 and 80%, respectively, in the two patients (Table II) . A small percentage of the absorbed dose (4.7 to 13.4%, mean 7.7%o) appeared in the urine during the first 24 hours. The urinary excretion measured in patient T.E. was 6.5%o of the absorbed dose.
The rate of formation of 14CO2 as a function of value observed is not known. Technical error is possible, and a repeat study is planned.
Both in the normal control subjects and in the patients, radioactive phytanic acid was demonstrable in the plasma lipids after administration of labeled phytol ( Figure 5 ). In the control subjects the labeled phytanic acid disappeared rapidly from the plasma, being almost completely gone by 24 hours. In contrast, labeled phytanic acid persisted at high levels in the patients' plasmas (Figure 5) . Traces (Figure  1 ), one would anticipate that 14 hydrogen atoms could be derived from reductive processes. However, the exact number of hydrogens derived from body water is uncertain because of the lack of sufficient information on 1) the extent of equilibration of reduced nucleotides with D2O and 2) the extent of exchange of labile hydrogens in intermediates (40) . Since at most 2 or 3 hydrogens were replaced by deuterium over a 4-month period on D2O, it can be immediately concluded that biosynthesis, if it occurs at all, must be extremely slow. Furthermore, the additional information obtained by analysis of the mass spectra, showing that enrichment was largely limited to the carboxyl-terminal fragment of the molecule (carbon atoms 1 through 3 together with the first branch-methyl group), strongly suggests that even the small incorporation observed does not reflect de novo synthesis. The latter should result in even distribution along the string of isoprene units. It could reflect exchange of hydrogen atoms alpha to the carboxyl carbon or reduction of unsaturated dietary precursors (such as phytol) to phytanic acid. The isotopic studies lead us to conclude that there is little or no endogenous biosynthesis from small molecules and that the phytanic acid accumulating must therefore have an exogenous origin. The results with phytol-14C establish it as a potential precursor.
Studies in this laboratory first demonstrated that normal experimental animals absorb dietary phytol and convert it to phytanic acid, and that the latter accumulates when phytol intake is high (13, 41) . These results have been confirmed and extended by Klenk and Kremer (14) . The present studies clearly establish that also in man dietary phytol-U-'4C is readily absorbed and converted to phytanic acid, both in normal subjects and in patients with Refsum's disease. Conversion of tritium-labeled phytol to phytanic acid in a patient with Refsum's disease has been reported by Stoffel and Kahlke (42) . When phytol is fed to rats at high dosages, phytanic acid accumulates in the tissues, accounting for as much as 20 to 30%o of the total fatty acids in liver and serum (13, 14) . Similar results have been obtained in the mouse, rabbit, and chinchilla (15) . Dietary phytanic acid (14, 15, 22, 39) is also absorbed by the rat and, when fed in sufficiently high dosage, also leads to accumulation of phytanic acid in tissues. Finally it has been shown in rats that 14C-labeled dihydrophytol is converted to phytanic acid (16, 43) and that feeding of dihydrophytol in large doses again causes accumulation of phytanic acid (14) . It should be stressed that, in order to cause significant accumulation of phytanic acid in normal experimental animals, very large daily doses of the various branched-chain precursors must be administered, i.e., the normal animal has the capacity to metabolize large amounts of these substrates (13-15, 22, 39 (9) . Patients T.E. and K.M. were observed over the period of a year during which their diet was modified to exclude as much as possible foods containing phytanic acid or phytol. After an initial period of several months during which there was little change, the plasma phytanic acid concentration began to fall progressively and went down to levels about one-fourth of the initial values. This lipid storage disease thus appears to be similar to phenylketonuria in that the accumulation of the abnormal substance depends upon the intake of precursors in the diet.
On the basis of all data presently available, we conclude that accumulation of phytanic acid in Refsum's disease is most probably due to a partial block in its degradation. The pathway for oxidation of phytanic acid has not been established.5 and little can be said regarding the exact nature of the enzyme defect. Because the /-methyl substitution precludes direct /8 oxidation, Eldjarn and coworkers have explored the possibility that an w-oxidizing system might be deficient in Refsum's disease. They have shown that in the w oxidation of capric acid, patients do have a decreased capacity compared to that of normal controls (48) . However, the patients' abilities to break down geraniol, 2,2-dimethylstearic acid, cholesterol, and vitamin E by w oxidation appeared to be normal (49). As discussed above, patients with Refsum's disease seem to have a complete block in the pathway for degradation of the model compound, 3,6-dimethyloctanoic acid (45) . Eldjarn, Try, and Stokke have therefore proposed that there may be two alternative pathways for phytanic acid degradation, one of which is still intact and one of which is very closely related at some point to that for degrading 3,6-dimethyloctanoic acid and is completely blocked. Alternatively, the impaired rate of metabolism could be due to attenuated activity of a single degradative pathway.
It is not yet established that phytanic acid accumulation in itself leads to the neurological changes in Refsum's disease. Preliminary evidence compatible with such a direct effect has 5 Since this paper was submitted, it has been shown in experimental animals that phytanic acid undergoes an initial alpha oxidation to yield 2,6,10,14-tetramethylpentadecanoic acid (46) and that this then is degraded by successive beta oxidations (47) .
been presented in connection with the dietary restriction studies referred to above, in which one patient showed some clinical improvement during the year on special diet (9) . Such a direct relationship might follow because incorporation of the branched-chain compound into myelin might distort its structure and make the membranes unstable. However, in studies to date, it has not been possible to evoke changes in nerve structure or function by feeding phytol or phytanic acid to experimental animals (15, 39) . Another possibility is that phytanic acid interferes with the function of fat-soluble vitamins with side-chains of more or less closely related structure (A, E, and K). On the other hand, the symptoms might be unrelated to phytanic acid accumulation per se. One or more of the steps in phytanic acid degradation may involve enzymes that are important also in other metabolic pathways. Thus a deficiency might lead to accumulation of phytanic acid and simultaneously, although independently, to distortions of metabolic pathways critical for normal nerve structure and function. Finally, there is the possibility that more than one gene is affected and that the defect in phytanic acid degradation is not functionally related to the error in nerve cell metabolism.
